April 21, 2020 -- Allterum Therapeutics has received a $2.9 million product development grant from the Cancer Research and Prevention Institute of Texas to support preclinical development of monoclonal antibodies for leukemia.
Specifically, the funds will be used to support preclinical development of 4A10 antibody therapy for the treatment of pediatric patients suffering from T-cell acute lymphoblastic leukemia, according to the company. This technology was licensed from the U.S. National Cancer Institute.
In addition, the funding will be utilized to support the drug manufacturing scale-up currently underway in partnership with contract development and manufacturing organization Fujifilm Diosynth Biotechnologies, Allterum said.
Copyright © 2020 scienceboard.net